skip to content

Market News

PureTech's Vedanta announces new collaborations

16 February 2017 09:15

PureTech Health notes Vedanta Biosciences has entered into clinical translational medicine collaborations with Stanford University School of Medicine and Leiden University Medical Center.

Under the terms of the agreement with Stanford, Vedanta would analyse changes in the gut microbiome as they relate to responses to oral immunotherapies in children with food allergies.

With Leiden University, Vedanta will generate clinical data from interventional studies of faecal transplantation in C. difficile patients, as well as clinical data from patients with graft-versus-host disease.

Both collaborations seek to better understand patterns in the microbiome that can potentially inform clinical responses to therapy and support Vedanta's ongoing drug development strategy.

At 9:15am: (LON:PRTC) Puretech Health Plc share price was -0.37p at 117.88p

Story provided by

Related Company: PRTC

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

Bluezest Aviva Aberdeen

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.